Skip to main content

Table 2 Primary outcome measures comparing rosuvastatin and aspirin to placebo, with 12 weeks follow-up as the primary comparison

From: Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin

 Rosuvastatin (n = 48)Aspirin (n = 40)Placebo (n = 42)Rosuvastatin vs placeboAspirin vs placeboRosuvastatin vs aspirin
Mean (SD)p valueDifferential changeb (95% CI)Effect sizecp valueDifferential changeb (95% CI)Effect sizecDifferential changeb (95% CI)
MADRS (depression)
 Overalla0.2960.467 
 Baseline32.6 (6.1)32.6 (5.5)32.3 (6.5)  
 4 weeks23.1 (10.2)22.7 (9.7)24.0 (9.2) − 1.6 (− 5.7, 2.5)− 0.210.357− 1.7 (− 5.4, 2.0)− 0.240.0 (− 4.3, 4.3)
 8 weeks19.1 (10.7)22.0 (11.1)22.1 (10.6) − 3.7 (− 8.1, 0.6)− 0.430.854− 0.4 (− 4.7, 3.9)− 0.073.5 (− 8.3, 1.2)
 12 weeks17.2 (11.0)22.9 (12.0)20.4 (12.4)0.089− 4.2 (− 9.1, 0.6)− 0.440.4331.9 (− 2.8, 6.6)0.16− 6.4 (− 11.7, 1.2)
 26 weeksd16.0 (12.3)15.7 (10.4)13.2 (10.4)0.4871.9 (− 3.4, 7.2)0.120.3532.5 (− 2.7, 7.6)0.100.3 (− 6.0, 6.7)
  1. MADRS Montgomery-Asberg Depression Rating Scale
  2. aIntervention by follow-up interaction test
  3. bTwo-way interaction of intervention allocation and measurement time (baseline adjusted between group mean difference estimated from GEE model)
  4. cCohen’s d effect size
  5. dFrom a GEE model that includes baseline and week 4 to week 26 measures